Peregrine Pharma (PPHM) Will Present Topline Data from Bavituximab Phase 3 in NSCLC at ESMO 2016
Go back to Peregrine Pharma (PPHM) Will Present Topline Data from Bavituximab Phase 3 in NSCLC at ESMO 2016| PEREGRINE PHARMA (NASDAQ: PPHM) | Delayed: 0.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.61 | 52 Week High | $1.33 | |||
| Open | $13.94 | 52 Week Low | $0.29 | |||
| Day High | $0.61 | P/E | N/A | |||
| Day Low | $0.61 | EPS | $-0.50 | |||
| Volume | 660 | |||||
| PEREGR 10.5% CP-E (NASDAQ: PPHMP) | Delayed: 24.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.62 | 52 Week High | $24.00 | |||
| Open | $0.12 | 52 Week Low | $8.19 | |||
| Day High | $24.62 | P/E | N/A | |||
| Day Low | $24.62 | EPS | $0.00 | |||
| Volume | 583,356 | |||||
